Citation Impact
Citing Papers
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer
2017
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
2018
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Approximate Bayesian Inference for Latent Gaussian models by using Integrated Nested Laplace Approximations
2009 Standout
Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody
2016
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
2019
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
2012
Review of Studies on the Effect of Bile Acid Sequestrants in Patients with Type 2 Diabetes Mellitus
2010
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Myeloid-derived suppressor cells coming of age
2018 Standout
Top 10 Challenges in Cancer Immunotherapy
2020
Biomarkers of response to PD-1/PD-L1 inhibition
2017
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
2021
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
2017
Navigating the multiple meanings of β diversity: a roadmap for the practicing ecologist
2010 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile
2014 StandoutNature
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
2019
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
2012
Hepatocellular carcinoma
2021 Standout
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
2018
The immune contexture in cancer prognosis and treatment
2017 Standout
Bile acid sequestrants
2011
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
2019
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
2017
Beyond intestinal soap—bile acids in metabolic control
2014
Delivery technologies for cancer immunotherapy
2019 Standout
Gut microbiome and health: mechanistic insights
2022 Standout
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Combinations of Bevacizumab With Cancer Immunotherapy
2018
Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
2018
Targeting apoptosis in cancer therapy
2020 Standout
FORWARD SELECTION OF EXPLANATORY VARIABLES
2008 Standout
Drug development in the era of precision medicine
2017
Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients
2017
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
2016 Standout
The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review
2017
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
2016
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
2016
Type 2 diabetes mellitus
2015 Standout
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
2017
Molecular therapies and precision medicine for hepatocellular carcinoma
2018
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
2018
VARIATION PARTITIONING OF SPECIES DATA MATRICES: ESTIMATION AND COMPARISON OF FRACTIONS
2006 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Hepatocellular Carcinoma
2019 Standout
Modelling count data with overdispersion and spatial effects
2006
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
2017
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
2020
Bladder Cancer
2020 Standout
Spatial modelling: a comprehensive framework for principal coordinate analysis of neighbour matrices (PCNM)
2006 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 Standout
Methods to account for spatial autocorrelation in the analysis of species distributional data: a review
2007 Standout
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
2018
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
A minimally designed PD-L1-targeted nanocomposite for positive feedback-based multimodal cancer therapy
2022
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Photothermal Nanomaterials: A Powerful Light-to-Heat Converter
2023 Standout
Adaptive Gaussian Markov Random Fields with Applications in Human Brain Mapping
2007
Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review*
2013
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
An Explicit Link between Gaussian Fields and Gaussian Markov Random Fields: The Stochastic Partial Differential Equation Approach
2011 Standout
Works of Xiaoping Jin being referenced
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
2016
Initial Combination Therapy with Metformin and Colesevelam for Achievement of Glycemic and Lipid Goals Min Early Type 2 Diabetes
2010
Colesevelam Hydrochloride to Treat Hypercholesterolemia and Improve Glycemia in Prediabetes: A Randomized, Prospective Study
2010
Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.
2016
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
2017
Generalized Hierarchical Multivariate CAR Models for Areal Data
2005
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
2016
Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.
2017
Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer
2013
Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors.
2015
Relationship of baseline tumoral IFNγ mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients.
2016
Association of liver metastases (LM) with survival in NSCLC patients treated with durvalumab (D) in two independent clinical trials.
2017
Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).
2017